{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:05:56Z","timestamp":1760731556471,"version":"3.44.0"},"reference-count":25,"publisher":"The Pediatric Pharmacy Association","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,12,1]]},"abstract":"<jats:sec>\n                  <jats:title>OBJECTIVE<\/jats:title>\n                  <jats:p>Delirium and agitation can be devastating and prolong the length of hospitalization. As part of our continuous improvement efforts, we implemented the use of intermittent chlorpromazine therapy to target refractory agitation associated with hyperactive or mixed delirium (RAA-D). The purpose of this study was to evaluate the effectiveness of chlorpromazine on RAA-D and delirium symptoms as well as any adverse effects in critically ill children.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>METHODS<\/jats:title>\n                  <jats:p>Retrospective chart review was conducted for children admitted to the pediatric intensive care unit who were treated with chlorpromazine for RAA-D from March 2017 to January 2019. The primary end point was to determine differences in Cornell Assessment for Pediatric Delirium (CAPD) and State Behavioral Scale (SBS) scores 24 hours before and after chlorpromazine administration. The secondary end points were the 24-hour cumulative dosing of narcotic and sedative agents before and after chlorpromazine administration and adverse events associated with chlorpromazine use.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>Twenty-six patients were treated with chlorpromazine for RAA-D; 16 (61.5%) were male with a median age of 14.5 months (IQR, 6\u201348). The mean CAPD (n = 24) and median SBS (n = 23) scores were significantly lower 24 hours after chlorpromazine use when compared to baseline scores, 12 vs 8.9 (p = 0.0021) and 1 vs \u22121, (p = 0.0005) respectively. No significant adverse effects were observed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>Chlorpromazine use in critically ill children with RAA-D was helpful for managing symptoms without adverse events. Further investigation is needed to evaluate the use of chlorpromazine to treat RAA-D to avoid long-term use of an antipsychotic.<\/jats:p>\n               <\/jats:sec>","DOI":"10.5863\/1551-6776-27.8.725","type":"journal-article","created":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T18:20:46Z","timestamp":1668709246000},"page":"725-731","source":"Crossref","is-referenced-by-count":1,"title":["Chlorpromazine as Treatment for Refractory Agitation Associated with Pediatric Delirium"],"prefix":"10.5863","volume":"27","author":[{"given":"Shin Young","family":"Kim","sequence":"first","affiliation":[{"name":"Department of Pharmacy (SYK), University of Maryland School of Pharmacy, Baltimore, MD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shari","family":"Simone","sequence":"additional","affiliation":[{"name":"Department of Pediatrics (SS, ALG), University of Maryland School of Medicine, Baltimore, MD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omayma A.","family":"Kishk","sequence":"additional","affiliation":[{"name":"Department of Pharmacy (OAK), University of Maryland Medical Center, Baltimore, MD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Lia","family":"Graciano","sequence":"additional","affiliation":[{"name":"Department of Pediatrics (SS, ALG), University of Maryland School of Medicine, Baltimore, MD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyunuk","family":"Seung","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Science (HS), University of Maryland School of Pharmacy, Baltimore, MD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Edwards","sequence":"additional","affiliation":[{"name":"Department of Psychiatry (SE), University of Maryland School of Medicine, Baltimore, MD"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3883","published-online":{"date-parts":[[2022,11,17]]},"reference":[{"key":"2022111718184175700_i2331-348X-27-8-725-b1","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association.","year":"2013","edition":"5 ed"},{"issue":"5","key":"2022111718184175700_i2331-348X-27-8-725-b2","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.pcl.2017.06.009","article-title":"Delirium in pediatric critical care","volume":"64","author":"Patel","year":"2017","journal-title":"Pediatr Clin N Am"},{"issue":"1","key":"2022111718184175700_i2331-348X-27-8-725-b3","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/PCC.0000000000002126","article-title":"Delirium in a tertiary PICU: risk factors and outcomes","volume":"21","author":"Dervan","year":"2020","journal-title":"Pediatr Crit Care Med"},{"issue":"9","key":"2022111718184175700_i2331-348X-27-8-725-b4","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1097\/CCM.0000000000003194","article-title":"Benzodiazepines and development of delirium in critically ill children: estimating the causal effect","volume":"46","author":"Mody","year":"2018","journal-title":"Crit Care Med"},{"issue":"9","key":"2022111718184175700_i2331-348X-27-8-725-b5","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1097\/CCM.0000000000002515","article-title":"Delirium and benzodiazepines associated with prolonged ICU stay in critically ill children and young children","volume":"45","author":"Smith","year":"2017","journal-title":"Crit Care Med"},{"issue":"5","key":"2022111718184175700_i2331-348X-27-8-725-b6","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1097\/CCM.0000000000002324","article-title":"Delirium and mortality in critically ill children: epidemiology and outcomes of pediatric delirium","volume":"45","author":"Traube","year":"2017","journal-title":"Crit Care Med"},{"issue":"12","key":"2022111718184175700_i2331-348X-27-8-725-b7","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s11920-017-0851-1","article-title":"Pediatric delirium: recognition, management and outcome","volume":"19","author":"Turkel","year":"2017","journal-title":"Curr Psychiatry Rep"},{"issue":"6","key":"2022111718184175700_i2331-348X-27-8-725-b8","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1097\/PCC.0000000000001127","article-title":"Implementation of an ICU bundle: an interprofessional quality improvement project to enhance delirium management and monitor delirium prevalence in a single PICU","volume":"18","author":"Simone","year":"2017","journal-title":"Pediatr Crit Care Med"},{"issue":"2","key":"2022111718184175700_i2331-348X-27-8-725-b9","first-page":"81","article-title":"Antipsychotic use in the prevention and treatment of intensive care unit delirium in pediatric patients","volume":"25","author":"Capino","year":"2020","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"65","key":"2022111718184175700_i2331-348X-27-8-725-b10","first-page":"1","article-title":"Pediatric delirium: evaluation, management, and special considerations","volume":"19","author":"Malas","year":"2017","journal-title":"Curr Psychiatry Rep"},{"issue":"9","key":"2022111718184175700_i2331-348X-27-8-725-b11","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1089\/cap.2015.0093","article-title":"Evaluation of the safety of quetiapine in treating delirium in critically ill children: a retrospective review","volume":"25","author":"Joyce","year":"2015","journal-title":"J Child Adolesc Psych Pharm"},{"issue":"3","key":"2022111718184175700_i2331-348X-27-8-725-b12","first-page":"204","article-title":"Antipsychotic treatment of delirium in critically ill children: a retrospective matched cohort study","volume":"24","author":"Kishk","year":"2019","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"2","key":"2022111718184175700_i2331-348X-27-8-725-b13","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/00000542-200108000-00007","article-title":"A double-blind, randomized comparison of I.V. lorazepam versus midazolam for sedation of ICU patients via a pharmacologic model","volume":"95","author":"Barr","year":"2001","journal-title":"Anesthesiology"},{"key":"2022111718184175700_i2331-348X-27-8-725-b14","volume-title":"Pediatric Neonatal Dosage Handbook","author":"Taketomo","year":"2015","edition":"21st ed"},{"issue":"2","key":"2022111718184175700_i2331-348X-27-8-725-b15","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1345\/aph.1H421","article-title":"Opioid conversions in acute care","volume":"41","author":"Patanwala","year":"2007","journal-title":"Ann Pharmacother"},{"key":"2022111718184175700_i2331-348X-27-8-725-b16","volume-title":"Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain","author":"American Pain Society.","year":"2008","edition":"6th ed"},{"issue":"4","key":"2022111718184175700_i2331-348X-27-8-725-b17","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/SPC.0000000000000236","article-title":"Neuroleptics in the management of delirium in patients with advanced cancer","volume":"10","author":"Hui","year":"2016","journal-title":"Curr Opin Support Palliat Care"},{"year":"2020","key":"2022111718184175700_i2331-348X-27-8-725-b18","article-title":"Chlorpromazine hydrochloride (injection) [package insert]"},{"key":"2022111718184175700_i2331-348X-27-8-725-b19","unstructured":"Compound summary for CID 2726, chlorpromazine.\n\t\t\t\t\tAccessed September 20, 2020. https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Chlorpromazine"},{"key":"2022111718184175700_i2331-348X-27-8-725-b20","doi-asserted-by":"crossref","DOI":"10.1027\/00496-000","volume-title":"Clinical Handbook for Psychotropic Drugs","author":"Procyshyn","year":"2017","edition":"22nd ed"},{"issue":"2","key":"2022111718184175700_i2331-348X-27-8-725-b21","first-page":"231","article-title":"A double-blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients","volume":"153","author":"Breitbart","year":"2005","journal-title":"Focus"},{"issue":"9","key":"2022111718184175700_i2331-348X-27-8-725-b22","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1089\/jpm.2017.0669","article-title":"Factors associated with the effectiveness of intravenous administration of chlorpromazine for delirium in patients with terminal cancer","volume":"21","author":"Hasuo","year":"2018","journal-title":"J Palliat Med"},{"issue":"3","key":"2022111718184175700_i2331-348X-27-8-725-b23","doi-asserted-by":"crossref","first-page":"399","DOI":"10.4143\/crt.2013.229","article-title":"Frequency and outcome of neuroleptic rotation in the management of delirium in patients with advanced cancer","volume":"47","author":"Shin","year":"2015","journal-title":"Cancer Res Treat"},{"issue":"4","key":"2022111718184175700_i2331-348X-27-8-725-b24","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1176\/jnp.15.4.431","article-title":"Delirium in children and adolescents","volume":"15","author":"Turkel","year":"2003","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"10","key":"2022111718184175700_i2331-348X-27-8-725-b25","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1176\/appi.ajp.2010.09111606","article-title":"Infant delirium in pediatric critical care settings","volume":"167","author":"Silver","year":"2010","journal-title":"Am J Psychiatry"}],"container-title":["The Journal of Pediatric Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/meridian.allenpress.com\/jppt\/article-pdf\/27\/8\/725\/3147368\/i2331-348x-27-8-725.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/meridian.allenpress.com\/jppt\/article-pdf\/27\/8\/725\/3147368\/i2331-348x-27-8-725.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T18:30:12Z","timestamp":1738780212000},"score":1,"resource":{"primary":{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/27\/8\/article-p725.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,17]]},"references-count":25,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,11,17]]},"published-print":{"date-parts":[[2022,12,1]]}},"URL":"https:\/\/doi.org\/10.5863\/1551-6776-27.8.725","relation":{},"ISSN":["2331-348X","1551-6776"],"issn-type":[{"type":"electronic","value":"2331-348X"},{"type":"print","value":"1551-6776"}],"subject":[],"published":{"date-parts":[[2022,11,17]]}}}